{"groups":[{"description":"Participants apply a low dose (3.25 mg) of vaginal prasterone (dehydroepiandrosterone \\[DHEA\\]) gel once daily (QD), at bed time, for 12 weeks. Treatment continues until unacceptable adverse events or patient refusal to continue participation on the study.","id":"FG000","title":"Arm I Low Dose DHEA"},{"description":"Participants apply a high dose (6.5 mg) of vaginal DHEA gel QD, at bed time, for 12 weeks. Treatment continues until unacceptable adverse events or patient refusal to continue participation on the study.","id":"FG001","title":"Arm II High Dose DHEA"},{"description":"Participants apply a vaginal placebo gel QD, at bed time, for 12 weeks.\n\nThere is an Optional Continuation Phase (for placebo arm only): Participants apply a high dose of vaginal DHEA gel QD, at bed time, for 12 weeks. Treatment continues until unacceptable adverse events or patient refusal to continue participation on the study.","id":"FG002","title":"Arm III Placebo"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"10"},{"groupId":"FG001","numSubjects":"16"},{"groupId":"FG002","numSubjects":"13"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"13"},{"groupId":"FG001","numSubjects":"17"},{"groupId":"FG002","numSubjects":"14"}],"type":"Adverse Event"},{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"2"},{"groupId":"FG002","numSubjects":"1"}],"type":"Unkown"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"1"}],"type":"Alternative Treatment"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"147"},{"groupId":"FG001","numSubjects":"149"},{"groupId":"FG002","numSubjects":"147"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"123"},{"groupId":"FG001","numSubjects":"114"},{"groupId":"FG002","numSubjects":"118"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"24"},{"groupId":"FG001","numSubjects":"35"},{"groupId":"FG002","numSubjects":"29"}],"type":"NOT COMPLETED"}],"title":"Raondomized Treatment"},{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"comment":"Patients completing Arm III Placebo were offered the option of continuing High Dose DHEA","groupId":"FG002","numSubjects":"94"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"94"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Optional Continuation Phase"}],"preAssignmentDetails":"A total of 464 patients were accrued to this trial. Nineteen patients withdrew consent prior to randomization and were not included in the analysis of this study. Two additional patients were unable to classify the primary symptom and were not randomized to the trial and were not included in the analysis."}